Ocean Biomedical (NASDAQ: OCEA) Announces Enrollment of Patients for Phase 1b Study for Chronic Hepatitis B Treatment in 50-50 Joint Venture with Virion Therapeutics
October 17, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Providence, Rhode Island, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top...
Chronic Hepatitis B Market to Observe Stunning Growth at a CAGR of 13.4% by 2032 | DelveInsight
May 16, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, May 16, 2023 (GLOBE NEWSWIRE) -- Chronic Hepatitis B Market to Observe Stunning Growth at a CAGR of 13.4% by 2032 | DelveInsight The chronic hepatitis B market is expected to grow...
Global Chronic Hepatitis B (CHB) Market to Reach USD 6.1 Billion by 2031: Says AMR
November 01, 2022 03:38 ET
|
Allied Market Research
Portland, OR, Nov. 01, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Chronic Hepatitis B (CHB) Market size was estimated at $4.6 billion in 2021...
Arbutus to Present Seven Scientific Posters at EASL International Liver Congress™ 2022
June 08, 2022 02:05 ET
|
Arbutus Biopharma Corporation
Conference Call & Webcast to discuss new data being presented at EASL ILC 2022 scheduled for June 27, 2022 at 8:00 am ETWARMINSTER, Pa., June 08, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma...
Chronic Hepatitis B Pipeline Analysis: Emerging Therapies, Key Companies, and Treatment Outlook | DelveInsight
May 11, 2022 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, May 11, 2022 (GLOBE NEWSWIRE) -- Chronic Hepatitis B Pipeline Analysis: Emerging Therapies, Key Companies, and Treatment Outlook | DelveInsight Chronic Hepatitis B Pipeline...